# Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer

> **NCT03596281** · PHASE1 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 47 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Bevacizumab
- **DRUG:** pegylated liposomal doxorubicin (PLD)

## Key facts

- **NCT ID:** NCT03596281
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-05
- **Primary completion:** 2021-03-11
- **Final completion:** 2023-04-11
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03596281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03596281, "Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03596281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*